Literature DB >> 16338226

Intratracheal gene transfer of tissue factor pathway inhibitor attenuates pulmonary fibrosis.

Naoki Kijiyama1, Hikaru Ueno, Isamu Sugimoto, Yasuyuki Sasaguri, Kazuhiro Yatera, Masamitsu Kido, Esteban C Gabazza, Koji Suzuki, Eikichi Hashimoto, Hiroyuki Takeya.   

Abstract

Activation of the coagulation system and increased expression of tissue factor (TF) in pulmonary fibrosis associated with acute and chronic lung injury have been previously documented. In the present study, we evaluated the effect of TF inhibition with intratracheal gene transfer of tissue factor pathway inhibitor (TFPI), a potent and highly specific endogenous inhibitor of TF-dependent coagulation activation, in a rat model of bleomycin-induced lung fibrosis. Significant lung fibrotic changes as assessed by histologic findings and hydroxyproline content, and increased procoagulant activity and thrombin generation in bronchoalveolar lavage fluid were detected in rats after intratracheal injection of bleomycin. Intratracheal administration of an adenovirus vector expressing TFPI significantly decreased bleomycin-induced procoagulant and thrombin generation resulting in a strong inhibition of pulmonary fibrosis. TFPI-overexpression in the lung was associated with a significant reduction in gene expression of the connective tissue growth factor, a potent profibrotic growth factor. This is the first report showing that direct inhibition of TF-mediated coagulation activation abrogates bleomycin-induced pulmonary fibrosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16338226     DOI: 10.1016/j.bbrc.2005.11.127

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  The Therapeutic Potential of Anticoagulation in Organ Fibrosis.

Authors:  Hanna Oh; Hye Eun Park; Min Su Song; HaYoung Kim; Jea-Hyun Baek
Journal:  Front Med (Lausanne)       Date:  2022-05-16

2.  LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis.

Authors:  Thomas R Cox; Demelza Bird; Ann-Marie Baker; Holly E Barker; Melisa W-Y Ho; Georgina Lang; Janine T Erler
Journal:  Cancer Res       Date:  2013-01-23       Impact factor: 12.701

Review 3.  Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention?

Authors:  R C Chambers
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

4.  Pulmonary epithelium is a prominent source of proteinase-activated receptor-1-inducible CCL2 in pulmonary fibrosis.

Authors:  Paul F Mercer; Robin H Johns; Chris J Scotton; Malvina A Krupiczojc; Melanie Königshoff; David C J Howell; Robin J McAnulty; Anuk Das; Andrew J Thorley; Terry D Tetley; Oliver Eickelberg; Rachel C Chambers
Journal:  Am J Respir Crit Care Med       Date:  2008-12-05       Impact factor: 21.405

5.  Venous Thromboembolism After Adult Lung Transplantation: A Frequent Event Associated With Lower Survival.

Authors:  Manuel L Ribeiro Neto; Marie Budev; Daniel A Culver; C Randall Lane; Marcelo Gomes; Xiao-Feng Wang; Paulo Novis Rocha; Mitchell A Olman
Journal:  Transplantation       Date:  2018-04       Impact factor: 4.939

Review 6.  The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

Authors:  Antje Moeller; Kjetil Ask; David Warburton; Jack Gauldie; Martin Kolb
Journal:  Int J Biochem Cell Biol       Date:  2007-08-30       Impact factor: 5.085

7.  Molecular and cellular mechanisms of pulmonary fibrosis.

Authors:  Nevins W Todd; Irina G Luzina; Sergei P Atamas
Journal:  Fibrogenesis Tissue Repair       Date:  2012-07-23

8.  Tissue factor, blood coagulation, and beyond: an overview.

Authors:  Arthur J Chu
Journal:  Int J Inflam       Date:  2011-09-20

Review 9.  Tissue factor as an initiator of coagulation and inflammation in the lung.

Authors:  Tom van der Poll
Journal:  Crit Care       Date:  2008-11-26       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.